BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nieto RR, Carrasco A, Corral S, Castillo R, Gaspar PA, Bustamante ML, Silva H. BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review. Front Psychiatry 2021;12:662407. [PMID: 34220575 DOI: 10.3389/fpsyt.2021.662407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Chumakov E, Dorofeikova M, Tsyrenova K, Petrova N. A Cross-Sectional Study on Associations Between BDNF, CRP, IL-6 and Clinical Symptoms, Cognitive and Personal Performance in Patients With Paranoid Schizophrenia. Front Psychiatry 2022;13:943869. [PMID: 35873262 DOI: 10.3389/fpsyt.2022.943869] [Reference Citation Analysis]
2 Wu Y, Du X, Yang R, Yue Y, Peng R, Wu S, Wang H, Zhou Y, Fang X, Yuan N, Li R, Zhang J, Zou S, Zhao X, Lyu X, Li Z, Zhang X, Zhang X. Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients With First-Episode and Drug-Naïve Schizophrenia. Front Psychiatry 2022;13:911384. [PMID: 35757201 DOI: 10.3389/fpsyt.2022.911384] [Reference Citation Analysis]
3 Di Majo D, Cacciabaudo F, Accardi G, Gambino G, Giglia G, Ferraro G, Candore G, Sardo P. Ketogenic and Modified Mediterranean Diet as a Tool to Counteract Neuroinflammation in Multiple Sclerosis: Nutritional Suggestions. Nutrients 2022;14:2384. [PMID: 35745113 DOI: 10.3390/nu14122384] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Swora E, Boberska M, Kulis E, Knoll N, Keller J, Luszczynska A. Physical Activity, Positive and Negative Symptoms of Psychosis, and General Psychopathology among People with Psychotic Disorders: A Meta-Analysis. J Clin Med 2022;11:2719. [PMID: 35628845 DOI: 10.3390/jcm11102719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Adan A, Navarro JF; on behalf of ADDISCHRONO Group. Protocol for Characterization of Addiction and Dual Disorders: Effectiveness of Coadjuvant Chronotherapy in Patients with Partial Response. JCM 2022;11:1846. [DOI: 10.3390/jcm11071846] [Reference Citation Analysis]
6 Gupta L, Hoffman KW. Exploring the intersection of the microbiome and the developing brain: Impacts on schizophrenia risk. Schizophr Res 2021:S0920-9964(21)00325-X. [PMID: 34483026 DOI: 10.1016/j.schres.2021.08.010] [Reference Citation Analysis]
7 Markiewicz R, Markiewicz-Gospodarek A, Dobrowolska B, Łoza B. Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial. Neural Plast 2021;2021:4488664. [PMID: 34434228 DOI: 10.1155/2021/4488664] [Reference Citation Analysis]